Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline

Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures.  All existing investors, including Newpath Partners, 8VC and Alexandria Venture Investments, also participated.